BACKGROUND AND PURPOSE: To clarify the clinical benefit derived from the combined modality therapy (CMT) comprised of chemotherapy and involved-field radiotherapy (XRT) for stage I and II @entity706 of the head and neck. MATERIAL AND METHODS: Of 143 @entity1 with @entity706 of the head and neck treated at the Yonsei @entity5 Center between 1976 and 1995, 104 @entity1 (XRT group) received involved-field XRT alone with a median dose of 50.4 Gy (range: 20-70 Gy), while 39 @entity1 (CMT group) received a median three cycles (range: 1-6 cycles) of chemotherapy before starting involved-field XRT. The response rate, patterns of failure, complications, and survival data of the XRT group were compared with those of the CMT group. RESULTS: Despite a higher response rate, local failure was the most common pattern of failure in @entity1 of the both groups. The patterns of failure, including the systemic relapse rate were not influenced by the addition of combination chemotherapy. Although both modalities were well tolerated by the majority of @entity1 , aberrant @entity1200 or medical illnesses, such as a @entity9058 , @entity295 , intractable @entity548 , or the evolution of second @entity5 were more frequently observed in @entity1 of the CMT group. The prognosis of @entity1 in the XRT group was relatively poor, with a 5-year overall actuarial survival rate of 38% and disease-free survival rate of 32%, respectively. However, their clinical outcome was not altered by the addition of systemic chemotherapy. Achieving complete remission was the most important prognostic factor on univariate and multivariate analyses, but treatment modality was not found to be a prognostic variable influencing survival. CONCLUSIONS: Involved-field XRT alone for @entity706 of the head and neck was insufficient to achieve an improved survival rate, but the combination of chemotherapy and involved-field XRT failed to demonstrate any therapeutic advantage over involved-field XRT alone.

Combined chemotherapy and radiation versus radiation alone in the management of localized XXXX of the head and neck.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity295 :: ('MESH:D018805', 'Disease') :: ['sepsis'] @entity706 :: ('MESH:D008223', 'Disease') :: ['angiocentric lymphomas', 'angiocentric lymphoma'] @entity9058 :: ('MESH:D051359', 'Disease') :: ['hemophagocytic syndrome'] @entity5 :: ('MESH:D009369', 'Disease') :: ['primary malignancies', 'Cancer'] @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhage'] @entity1200 :: ('MESH:D007154', 'Disease') :: ['immunologic disorders']
@entity706 :: (MESH:D008223,Disease) :: ['angiocentric lymphoma']
